Products

SOLIRIS® - (Eculizumab) Products

SOLIRIS® is a first-in-class terminal complement inhibitor which works by electively inhibiting activation of specific proteins in the complement system (c5 and c5b), which play a role in the treatment of multiple rare diseases.1

Nufactor carries SOLIRIS (Eculizumab):


Product
Manufacturer
FDA-Approved Indication
IMMUNOSUPPRESSANT
Product: SOLIRIS® (Eculizumab)
Manufacturer: Alexion
FDA-Approved Indication: Generalized myasthenia gravis (gMG),
Paroxysmal nocturnal hemoglobinuria (PNH),
Atypical hemolytic uremic syndrome (aHUS),
Neuromyelitis optica spectrum disorder (NMOSD)

1 Alexion Pharmaceuticals. Soliris® (Eculizumab). Alexion.com/products/Soliris

Click here for a SOLIRIS (Eculizumab) order form.